Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial (Q38985969)

8 September 2017

Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial (English)

1 reference

8 September 2017

1 reference

1 reference

Akira Mitsuhashi

1

1 reference

8 September 2017

Takako Kiyokawa

series ordinal

2

1 reference

8 September 2017

Yasunori Sato

series ordinal

3

1 reference

8 September 2017

Makio Shozu

series ordinal

4

1 reference

8 September 2017

language of work or name

English

0 references

publication date

10 June 2014

1 reference

8 September 2017

1 reference

8 September 2017

120

1 reference

8 September 2017

2986-2995

1 reference

8 September 2017

19

1 reference

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

8 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin induces apoptosis of pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Repositioning metformin for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Insulin resistance and cancer: epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Prospective evaluation of insulin resistance among endometrial cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

The Ki-67 protein: from the known and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Topoisomerase II: A specific marker for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Insulin resistance: a significant risk factor of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin prevents tobacco carcinogen--induced lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin is associated with improved survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

Metformin use and endometrial cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28853

21 January 2018

Identifiers

DOI

10.1002/CNCR.28853

1 reference

8 September 2017

1 reference